Advertisement

Immunologic Research

, Volume 16, Issue 1, pp 59–70 | Cite as

The Cd40 ligand

The center of the immune universe?
  • Iqbal S. Grewal
  • Richard A. Flavell
Article

Abstract

For several years, the primary function of CD40 ligand (CD40L) has been believed to be in regulation of contact-dependent, CD40-CD40L-mediated signals between B-and T-cells, which are essential for the regulation of thymus-dependent (TD) humoral immune responses. Recently, a flurry of reports indicate that CD40 is expressed by variety of cell types other than B-cells that include dendritic cells, follicular dendritic cells, monocytes, macrophages, fibroblasts, and endothelial cells. These studies show that CD40-CD40L interactions are important in inflammatory process. For the past few years, through the availability of CD40L-knockout mice, new data have emerged to support the belief that CD40L has many more functions than its role in TD humoral immunity. CD40L-deficient mice have provided significant information towards our understanding of the in vivo role of CD40L. The current picture that emerges indicates that CD40-CD40L interactions mediate many cell-mediated immune responses and T-cell-mediated effector functions that are required for proper functioning of the host defense system. This article focuses on the in vivo role of the CD40L in regulation of cell-mediated effector functions.

Key words

CD40L T-cell activation T-cell priming T-cell effector functions Autoimmunity Parasitic infections 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, vanKooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Ann Rev Immunol 1994; 12: 881–922.CrossRefGoogle Scholar
  2. 2.
    Armitage RJ, Fanslow WC, Strock-bine L, Sato TA, Clifford KN, Macduff BM, et al.: Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Cocks BG, de Waal MalefytR, Galizzi JP, de VriesJE, Aversa G: IL-13 induces proliferation and differentiation of human B-cells activated by the CD40 ligand. Intl Immunol 1993;5:657–663.CrossRefGoogle Scholar
  4. 4.
    Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy JY: Induction of human IgE synthesis in B-cells by mast cells and basophils. Nature 1993;365:340–343.PubMedCrossRefGoogle Scholar
  5. 5.
    Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L: Identification of a novel surface protein on activated CD4+ T cells that induces contactdependent B cell differentiation (help). J Exp Med 1992;175:1091–1101.PubMedCrossRefGoogle Scholar
  6. 6.
    Noelle RJ, Ledbetter JA, Aruffo A: CD40 and its ligand, an essential ligand-receptor pair for thymusdependent B-cell activation. Immunol Today 1992;13:431–433.PubMedCrossRefGoogle Scholar
  7. 7.
    Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Fanslow WC: Recombinant human CD40 ligand stimulates B-cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176:1543–1550.PubMedCrossRefGoogle Scholar
  8. 8.
    Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T-cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B-cell co-stimulatory activity. EMBO J 1992;11: 4313–4321.PubMedGoogle Scholar
  9. 9.
    Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA: Cloning of TRAP, a ligand for CD40 on human T-cells. Eur J Immunol 1992;22:3191–3194.PubMedCrossRefGoogle Scholar
  10. 10.
    Grewal IS, Flavell RA: CD40-CD40L interactions in T-cell activation. Immunol Rev 1996;153: in press.Google Scholar
  11. 11.
    Callard RE, Armitage RJ, Fanslow WC, Spriggs MK: CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993; 14:559–564.PubMedCrossRefGoogle Scholar
  12. 12.
    Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent immunity. II. Prolonged in vivo suppression of primary and secondary humoral immune responses by an antibody targeted to the CD40 ligand, gp39. J Exp Med 1993;178:1567–1575.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramesh N, Fuleihan R, Geha, R: Molecular pathology of X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Immunol Rev 1994;138:87–104.PubMedCrossRefGoogle Scholar
  14. 14.
    Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA: Mice deficient for the CD40 ligand. Immunity 1994;1:423–431.PubMedCrossRefGoogle Scholar
  15. 15.
    Renshaw BR, Fanslow WC, Armitage RJ, Cambell KA, Liggit D, Wright B, et al.: Humoral immune responses in CD40 liganddeficient mice. J Exp Med 1994;180: 1889–1900.PubMedCrossRefGoogle Scholar
  16. 16.
    Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H: The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994 ;1:167–178.PubMedCrossRefGoogle Scholar
  17. 17.
    Grewal IS, Xu J, Flavell RA: Impairment of antigenspecific T-cell priming in mice lacking CD40 ligand. Nature 1995;378: 617–620.PubMedCrossRefGoogle Scholar
  18. 18.
    Grewal IS, Flavell RA A central role of CD40 ligand in the regulation of CD4 T-cell responses. ImmunolToday 1996;17:410–414.Google Scholar
  19. 19.
    Grewal IS, Flavell RA: Role of CD40 ligand in immunity and autoimmunity; in Plotkin S, Fantini B (eds.)Immune Tolerance. Elsevier, Paris: 1996, in press.Google Scholar
  20. 20.
    Noelle RJ: CD40 and its ligand in host defense. Immunity 1996;4: 415–419.PubMedCrossRefGoogle Scholar
  21. 21.
    Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, Chess L: Functional interactions of T-cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995 ; 182:1857–1864.PubMedCrossRefGoogle Scholar
  22. 22.
    Eynon EE, Parker DC: Small B cells as antigenpresenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992;175:131–138.PubMedCrossRefGoogle Scholar
  23. 23.
    Fuchs EJ, Matzinger P:B cells turn off virgin but not memory T cells. Science 1992;258:1156–1159PubMedCrossRefGoogle Scholar
  24. 24.
    Linsley PS, Ledbetter JA.: The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11:191–212Google Scholar
  25. 25.
    Janeway CA Jr, Bottomly K: Signals and signs for lymphocyte responses. Cell 1994;76:275–285PubMedCrossRefGoogle Scholar
  26. 26.
    Jenkins MK: The ups and downs of T cell costimulation. Immunity 1994;1:443–446PubMedCrossRefGoogle Scholar
  27. 27.
    Ranhei, EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925–935.CrossRefGoogle Scholar
  28. 28.
    Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R: Studies on the interdependence of gp39 and B7 expression and function during antigenspecific immune responses. Eur J Immunol 1995; 25:596–603.PubMedCrossRefGoogle Scholar
  29. 29.
    Kearne, RR, Pape KA, Loh DY, Jenkins MK: Visualization of peptidespecific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;94:327–339.CrossRefGoogle Scholar
  30. 30.
    Wu Y, Xu J, Shinde S, Grewal, IS, Henderson T, Flavell RA, Liu Y: Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 1995;5:1303–1311.PubMedCrossRefGoogle Scholar
  31. 31.
    Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA., Green, WR, Xu J, Shultz LD, Roopesian D, Flavell RA, Loran F, Noelle RJ, Durie FH: In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995;2:645–653.PubMedCrossRefGoogle Scholar
  32. 32.
    Lin H, Boiling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Longterm acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donorspecific transfusion. J Exp Med 1993;178:1801–1808.PubMedCrossRefGoogle Scholar
  33. 33.
    Boiling SF, Lin H, Wei RQ, Linsley P, Turka LA: The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. J Surg Res 1994;57:60–64.CrossRefGoogle Scholar
  34. 34.
    Caux C, Massacrier C, Vanbervliet B, Dubois B, VanKootenC, Durand I, Banchereau J: Activation of human dendritic cells through CD40 crosslinking. J Exp Med 1994;180:1263–1272.PubMedCrossRefGoogle Scholar
  35. 35.
    Peguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, VanKooten C, Banchereau J, Schmitt D: Functional expression of CD40 antigen on human epidermal Langerhans cells. J Immunol 1995;155:4241–4247.PubMedGoogle Scholar
  36. 36.
    Cella M, Scheidegger D, Palmer-Lehman K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184;747–752.PubMedCrossRefGoogle Scholar
  37. 37.
    Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G: High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-10. J Exp Med 1996;184:741–746.PubMedCrossRefGoogle Scholar
  38. 38.
    Aversa G, Punnonen J, deVries JE: The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993;177:1575–1585.PubMedCrossRefGoogle Scholar
  39. 39.
    Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S: Membrane tumour necrosis factoralpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 1993;63:464–466.CrossRefGoogle Scholar
  40. 40.
    Rodriguez C, Roldan E, Navas G, Brieva JA: Essential role of tumor necrosis factoralpha in the differentiation of human tonsil in vivo induced B cells capable of spontaneous and highrate immunoglobulin secretion. Eur J Immunol 1993;23:1160–1164.PubMedCrossRefGoogle Scholar
  41. 41.
    Larrick JW, Wright SC:Cytotoxic mechanism of tumor necrosis factoralpha. FASEB J 1990;4: 3215–3223.PubMedGoogle Scholar
  42. 42.
    Hernandez-Caselles T, Stutman O: Immune functions of tumor necrosis factor. I. Tumor necrosis factor induces apoptosis of mouse thymocytes and can also stimulate or inhibit IL-6-induced proliferation depending on the concentration of mitogenic costimulation. J Immunol 1993; 151:3999–4012.PubMedGoogle Scholar
  43. 43.
    Notarangelo LD, Duse M, Ugazio AG: Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992;3:101–122.PubMedGoogle Scholar
  44. 44.
    Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: Prevention of collageninduced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261:1328–1330.PubMedCrossRefGoogle Scholar
  45. 45.
    Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470–1480.PubMedGoogle Scholar
  46. 46.
    Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Ciaassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499–2504.PubMedCrossRefGoogle Scholar
  47. 47.
    Griggs ND, Agersborg SS, Noelle RJ, Ledbetter JA, Linsley PS, Tung KS: The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med 1996;183:801–810.PubMedCrossRefGoogle Scholar
  48. 48.
    Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342–4346.PubMedCrossRefGoogle Scholar
  49. 49.
    Lehmann PV, Forsthuber T, Miller A, Sercarz EE: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155–157.PubMedCrossRefGoogle Scholar
  50. 50.
    McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182: 75–85.PubMedCrossRefGoogle Scholar
  51. 51.
    Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, Flavell RA: Requirement for CD40 ligand in costimulation induction, T cell activation and experimental allergic encephalomyelitis. Science 1996;273:1864–1867.PubMedCrossRefGoogle Scholar
  52. 52.
    Stout R, Suttles J: The many roles of CD40: CD40L interactions in cell-mediated inflammatory responses. Immunol Today 1996; 17:487–492.PubMedCrossRefGoogle Scholar
  53. 53.
    Stout R, Suttles J, Xu J, Grewal I, Flavell R: Impaired T cell-mediated macrophage activation in CD40 liganddeficient mice. J Immunol 1996;156:8–11.PubMedGoogle Scholar
  54. 54.
    Wagner DH Jr, Stout RD, Suttles J: Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994;24:3148–3154.PubMedCrossRefGoogle Scholar
  55. 55.
    Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D: Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917–4925.PubMedGoogle Scholar
  56. 56.
    Tao X, Stout RD: T-cell-mediated cognate signaling of nitric oxide production by macrophages. Requirements for macrophage activation by plasma membranes isolated from T cells. Eur J Immunol 1993;23:2916–2921.PubMedCrossRefGoogle Scholar
  57. 57.
    Tian L, Noelle RJ, Lawrence DA: Activated T-cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 1995;25: 306–309.PubMedCrossRefGoogle Scholar
  58. 58.
    Stout RD: Macrophage activation by T cells: cognate and noncognate signals. Curr Opinion Immunol 1993;5:398–403.CrossRefGoogle Scholar
  59. 59.
    Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995;25:1125–1128.PubMedCrossRefGoogle Scholar
  60. 60.
    Afonso LC, Scott P: Immune responses associated with susceptibility of C57BL/10 mice toLeishmania amazonensis. Infect Immun 1993;61:2952–2959.PubMedGoogle Scholar
  61. 61.
    Reiner SL, Locksley RM: The regulation of immunity toLeishmania major. Ann Rev Immunol 1995;13:151–177.CrossRefGoogle Scholar
  62. 62.
    Soong L, Xu J, Grewal IS, Kima P, Sun J, Longley JrBJ, Ruddle NH, McMohan-Pratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results is an enhanced susceptibility toLeishmania amazonensis infection. Immunity 1996; 4:263–273.PubMedCrossRefGoogle Scholar
  63. 63.
    Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed, SG, Maliszewski, CR: CD40 Ligand is required for protective cell-mediated immunity toLeishmania major. Immunity 1996;4:283–289.PubMedCrossRefGoogle Scholar
  64. 64.
    Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H: Protective role of CD40 inLeishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996;4:275–281.PubMedCrossRefGoogle Scholar
  65. 65.
    Borrow P, Tishon A, Lee S, Xu J, Grewal IS, Oldstone MB, Flavell RA: CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med 1996; 183:2129–2142.PubMedCrossRefGoogle Scholar
  66. 66.
    Whitemire JK, Slifka MK, Grewal IS, Flavell RA, Ahmed R: CD40 liganddeficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J Virol 1996;70:8375–8381.Google Scholar
  67. 67.
    Kasaian MT, Leite-Morris KA, Biron CA: The role of CD4+ cells in sustaining lymphocyte proliferation during lymphocytic choriomeningitis virus infection. J Immunol 1991;146:1955–1963.PubMedGoogle Scholar
  68. 68.
    Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM: Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994;68:4700–4704.PubMedGoogle Scholar
  69. 69.
    vonHerrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL: CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 1996;70: 1072–1079.Google Scholar
  70. 70.
    Ding L, Green JM, Thompson CB, Shevach EM: B7/CD28-dependent and independent induction of CD40 lig and expression. J Immunol 1995;155:5124–5132.PubMedGoogle Scholar
  71. 71.
    Jaiswal AI, Dubey C, Swain SL, Croft M, Regulation of CD401 igand expression on naive CD T cells: a role for TCR but not co-stimulatory signals. Intl. Immunol 1996; 8:275–285.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1997

Authors and Affiliations

  • Iqbal S. Grewal
    • 1
  • Richard A. Flavell
    • 1
  1. 1.Howard Hughes Medical Institute, Section of ImmunobiologyYale University School of MedicineNew Haven

Personalised recommendations